Robert D Goldney,* Laura J Fisher†
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
Robert Goldney is on a psychotropic drug advisory board for Wyeth Australia and Lundbeck Australia, and the study was supported by the companies noted in the previously-published Acknowledgements. He has also received travel assistance from Sanofi-Synthelabo Australia and speaker fees from several of the companies named in the Acknowledgements. Laura Fisher has received part-salary/funding for data analysis from the companies noted in the Acknowledgements.